AI / ML Innovations Stock Price, News & Analysis

AIML (AIMLF) has announced the formation of its Medical Advisory Board to guide the development and implementation of its AI-powered ECG signal-processing platforms MaxYield™ and CardioYield™. The board comprises six distinguished cardiovascular experts from leading institutions, including the University of Toronto and University of British Columbia. Peter Kendall, AIML's President and Chief Commercialization Officer, will chair the board, leveraging his 20+ years of experience in health technology commercialization.

The advisory board will focus on steering clinical direction, trial design, and real-world deployment of AIML's flagship AI platforms. Simultaneously, the company has launched its redesigned corporate website, AIML.Health, serving as an interactive platform for stakeholders.

AI/ML Innovations (AIML) has submitted a 510(k) premarket notification to the FDA for its MaxYield™ platform, a cloud-native solution designed to enhance ECG signal quality. The platform uses proprietary neural network algorithms to reduce noise and improve waveform clarity in ECG signals across 1- to 12-lead configurations for adult patients 18 and older.

MaxYield is compatible with both hospital-grade systems and mobile devices, targeting signal distortions common in mobile, wearable, and dynamic clinical environments. This submission follows AIML's prior Device Master File (MAF) filing, which could facilitate future collaborations with manufacturers for device integration.

Additionally, AIML granted 800,000 stock options to directors and consultants at an exercise price of $0.105, vesting quarterly over one year with a five-year expiration.

AIML Innovations (OTCQB: AIMLF) has appointed Michael Diamond to its Board of Directors, effective immediately. Diamond, who serves as the President of the Ontario Progressive Conservative Party and Principal of Upstream Strategy Group, brings extensive expertise in political strategy, regulatory affairs, and stakeholder engagement. The appointment aims to strengthen AIML's expansion of AI-powered health technologies across regulated markets.

As a public affairs and strategic communications expert, Diamond's experience at the intersection of politics, business, and innovation will support AIML's efforts to build partnerships and navigate policy environments. The company, through its subsidiaries and strategic partnerships, focuses on AI and machine learning applications in digital health and wellbeing solutions.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced the immediate departure of Tim Daniels from its Board of Directors. While stepping down from the Board, Daniels will continue supporting the company in an advisory capacity.

CEO Paul Duffy acknowledged Daniels' contributions to AIML's leadership and strategic direction during his tenure, expressing appreciation for his continued involvement as an advisor. The company stated it remains focused on strengthening its leadership and advisory network to support ongoing commercialization efforts and strategic growth initiatives.

AIML operates in the artificial intelligence and machine learning sectors, focusing on digital health and wellbeing solutions through its subsidiaries NeuralCloud Solutions, Quantum Sciences, AI Rx, and strategic partnership with Health Gauge (95.2% owned by AIML).

AI/ML Innovations Inc. (AIMLF) has announced a restructuring agreement dated April 11, 2025, modifying terms of its December 2024 acquisition of Quantum Sciences The revised agreement includes significant changes: reduction of consideration shares from 10,000,000 to 6,264,822, elimination of the previously established 4% royalties on cardiology products, and termination of the consulting agreement with Orsim Finance

Key modifications include establishing a new revenue sharing agreement, transferring meApp intellectual property rights to Mark Orsmond, and implementing a one-time cash payment. The restructuring aims to enhance capital efficiency and streamline operational models, particularly in AI-powered health solutions. The agreement remains subject to Canadian Securities Exchange approval and other closing conditions.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced the appointment of Jared Adelstein to its Board of Directors, effective immediately. This strategic addition aims to strengthen the company's governance and accelerate commercialization efforts in the AI-powered healthcare space.

Adelstein brings strategic, financial, and operational expertise in guiding high-growth companies through important development stages. The appointment aligns with AIML's mission to deliver innovative AI solutions in healthcare and enhance its leadership team during a period of strategic growth.

AIML operates through its subsidiaries Quantum Sciences , NeuralCloud Solutions Inc, AI Rx Inc., and maintains strategic partnerships with Health Gauge Inc. (95.2% owned by AIML). The company focuses on AI and machine learning applications in digital health and wellbeing solutions.

AI/ML Innovations (AIMLF) has successfully completed an oversubscribed non-brokered private placement, raising $2,165,900 by issuing 43,318,000 units at $0.05 per unit. Each unit includes one common share and one warrant exercisable at $0.15 until April 15, 2028.

The company paid $101,815 in finder's fees and issued 1,917,300 finder's warrants. Company insiders participated significantly, with CEO Paul Duffy acquiring 4,250,000 units and President Peter Kendall purchasing 3,000,000 units. The proceeds will be used for general working capital.

Additionally, AIMLF modified terms for existing warrants from June 2023, simplifying the previous escalating exercise price structure to a fixed $0.20 exercise price for both 14,827,792 share purchase warrants and 411,800 broker warrants.

AI/ML Innovations Inc. (AIMLF) has announced updates to its non-brokered private placement offering, planning to issue up to 40,000,000 units at $0.05 per unit to raise gross proceeds of up to $2,000,000.

Each unit consists of one Common Share and one Warrant, with the Warrant term extended to three years from the previously announced two years. Warrant holders can purchase one Common Share at $0.15 per share, with no acceleration clause. The securities will have a four-month and one-day hold period.

The company plans to use the net proceeds for working capital requirements. Qualified finders assisting in unit sales will receive finder's fees in cash, securities, or both. The private placement requires approvals, including from the Canadian Securities Exchange.